News Release
Mallinckrodt Pharmaceuticals to Hold Investor Briefing October 14, 2014, in New York
Company to Provide Fiscal Year 2015 Financial Guidance
DUBLIN--(BUSINESS WIRE)--Sep. 2, 2014--
Mallinckrodt
plc. (NYSE: MNK), a leading global specialty pharmaceutical company,
will hold an investor briefing on Tuesday, October 14, 2014, in New York
City. Mark Trudeau, President and Chief Executive Officer of
Mallinckrodt, will present along with members of Mallinckrodt’s senior
management team. The presentation will include announcement of the
company’s fiscal year 2015 financial guidance.
The briefing will take place from 9 a.m. to 11 a.m. Eastern Time at The
Plaza, 770 Fifth Ave., New York, NY 10019. Those interested in attending
should register by contacting investor.relations@mallinckrodt.com.
Individuals unable to attend the briefing in person can view a live
webcast at Mallinckrodt’s Investor Relations website: http://www.mallinckrodt.com/investor_relations/.
The briefing is also available live via conference call at
1-844-867-9755 in the United States and 901-300-3301 outside the United
States; all callers should use the access code 95905912.
The presentation replay and materials will be available for a seven-day
period on the Mallinckrodt Investor Relations website following the end
of the event.
ABOUT MALLINCKRODT:
Mallinckrodt is a global specialty pharmaceutical and medical imaging
business that develops, manufactures, markets and distributes specialty
pharmaceutical products and medical imaging agents. Areas of focus
include therapeutic drugs for autoimmune and rare disease specialty
areas like neurology, rheumatology, nephrology and pulmonology along
with analgesics and central nervous system drugs for prescribing by
office- and hospital-based physicians. The company’s core strengths
include the acquisition and management of highly regulated raw
materials; deep regulatory expertise; and specialized chemistry,
formulation and manufacturing capabilities. The company’s Specialty
Pharmaceuticals segment includes branded and specialty generic drugs and
active pharmaceutical ingredients, and the Global Medical Imaging
segment includes contrast media and nuclear imaging agents. Mallinckrodt
has more than 5,500 employees worldwide and a commercial presence in
roughly 65 countries. The company’s fiscal 2013 revenue totaled $2.2
billion. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Source: Mallinckrodt
Mallinckrodt
Rhonda Sciarra, 314-654-8618
Manager,
Communications
rhonda.sciarra@mallinckrodt.com
or
Meredith
Fischer, 314-654-3318
Senior Vice President, Communications
meredith.fischer@mallinckrodt.com
or
John
Moten, 314-654-6650
Vice President, Investor Relations
john.moten@mallinckrodt.com
